Loading…
A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment
Treatment with glucocorticoids is associated with lower bone mineral density (BMD). We performed a genome-wide association study to analyze interactive effects between genotypes and cumulative dose of prednisone (PD) over 4.3 years of follow-up period on the final BMD Z -scores in 461 white children...
Saved in:
| Published in: | The pharmacogenomics journal 2017-03, Vol.17 (2), p.180-185 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3 |
| container_end_page | 185 |
| container_issue | 2 |
| container_start_page | 180 |
| container_title | The pharmacogenomics journal |
| container_volume | 17 |
| creator | Park, H-W Tse, S Yang, W Kelly, H W Kaste, S C Pui, C-H Relling, M V Tantisira, K G |
| description | Treatment with glucocorticoids is associated with lower bone mineral density (BMD). We performed a genome-wide association study to analyze interactive effects between genotypes and cumulative dose of prednisone (PD) over 4.3 years of follow-up period on the final BMD
Z
-scores in 461 white children from the Childhood Asthma Management Program. No variants met the conventional criteria for genome-wide significance, and thus we looked for evidence of replication. The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen. Among them, rs6461639 (interaction
P
=1.88 × 10
−5
in the CAMP population) showed a significant association with the final BMD
Z
-scores in the ALL population (
P
=0.016). The association of the ALL population was only present after correction for the anti-metabolite treatment arm (high vs low dose). We have identified a novel SNP, rs6461639, showing a significant effect on the final BMD
Z
-scores in two independent pediatric populations after long-term high-dose PD treatment. |
| doi_str_mv | 10.1038/tpj.2015.92 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4980282</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2615530341</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3</originalsourceid><addsrcrecordid>eNqNks9rFDEUxwex2Fo9eZeAF8HOmmTyay5CKVoLBS8K3kIm82Y2y0yyJhmX_vdm3VqqSOkpL7xPvt-8x7eqXhG8IrhR7_N2s6KY8FVLn1QnhMmmJoTjp79rXFPRfj-unqe0wZgIItWz6pgKxQVl8qTanaMRPGRn0WBsDhGZlIJ1JkOPdi6v0RR2aHDeTKgLHtDsPMRy6cEnl2-Q88iu3dRH8MgMGYpAeeLHupQzGqfFBhti0Q-uTyhHMHkGn19UR4OZEry8PU-rb58-fr34XF9_uby6OL-uLccy143EjFolMOedogOXqpNYYiMEAYGpwtB0YmBdZ4jkLWDc855R0lCqCPSma06rDwfd7dLN0NtiXX6vt9HNJt7oYJz-u-PdWo_hp2atKvq0CLy9FYjhxwIp69klC9NkPIQlaaJaohRmrHkESoXghEpW0Df_oJuwxLLkpKkgnDe4YeQhqniWOSVr20K9O1A2hpQiDHfTEaz3CdElIXqfEN3u53l9fyF37J9IFODsAKTS8iPEe6b_0fsFTvjFug</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1884217499</pqid></control><display><type>article</type><title>A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment</title><source>Springer Nature</source><creator>Park, H-W ; Tse, S ; Yang, W ; Kelly, H W ; Kaste, S C ; Pui, C-H ; Relling, M V ; Tantisira, K G</creator><creatorcontrib>Park, H-W ; Tse, S ; Yang, W ; Kelly, H W ; Kaste, S C ; Pui, C-H ; Relling, M V ; Tantisira, K G</creatorcontrib><description>Treatment with glucocorticoids is associated with lower bone mineral density (BMD). We performed a genome-wide association study to analyze interactive effects between genotypes and cumulative dose of prednisone (PD) over 4.3 years of follow-up period on the final BMD
Z
-scores in 461 white children from the Childhood Asthma Management Program. No variants met the conventional criteria for genome-wide significance, and thus we looked for evidence of replication. The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen. Among them, rs6461639 (interaction
P
=1.88 × 10
−5
in the CAMP population) showed a significant association with the final BMD
Z
-scores in the ALL population (
P
=0.016). The association of the ALL population was only present after correction for the anti-metabolite treatment arm (high vs low dose). We have identified a novel SNP, rs6461639, showing a significant effect on the final BMD
Z
-scores in two independent pediatric populations after long-term high-dose PD treatment.</description><identifier>ISSN: 1470-269X</identifier><identifier>ISSN: 1473-1150</identifier><identifier>EISSN: 1473-1150</identifier><identifier>DOI: 10.1038/tpj.2015.92</identifier><identifier>PMID: 26856247</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>45/43 ; 631/208/2489 ; 692/499 ; Absorptiometry, Photon ; Acute lymphoblastic leukemia ; Age Factors ; Anti-Asthmatic Agents - administration & dosage ; Anti-Asthmatic Agents - adverse effects ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Asthma ; Asthma - drug therapy ; Biomedical and Life Sciences ; Biomedicine ; Bone density ; Bone Density - drug effects ; Bone Density - genetics ; Bone mineral density ; Child ; Children ; Drug Administration Schedule ; Female ; Gene Expression ; Genome-wide association studies ; Genome-Wide Association Study ; Genomes ; Genotype ; Glucocorticoids ; Glucocorticoids - administration & dosage ; Glucocorticoids - adverse effects ; Human Genetics ; Humans ; Lymphatic leukemia ; Male ; Oncology ; original-article ; Pediatrics ; Pharmacogenetics ; Pharmacogenomic Variants ; Pharmacotherapy ; Phenotype ; Polymorphism, Single Nucleotide ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Prednisone ; Prednisone - administration & dosage ; Prednisone - adverse effects ; Psychopharmacology ; Replication ; Risk Factors ; Single-nucleotide polymorphism ; Time Factors ; Tomography, Spiral Computed ; Treatment Outcome ; United States</subject><ispartof>The pharmacogenomics journal, 2017-03, Vol.17 (2), p.180-185</ispartof><rights>Macmillan Publishers Limited 2016</rights><rights>Copyright Nature Publishing Group Mar 2017</rights><rights>Macmillan Publishers Limited 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3</citedby><cites>FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26856247$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, H-W</creatorcontrib><creatorcontrib>Tse, S</creatorcontrib><creatorcontrib>Yang, W</creatorcontrib><creatorcontrib>Kelly, H W</creatorcontrib><creatorcontrib>Kaste, S C</creatorcontrib><creatorcontrib>Pui, C-H</creatorcontrib><creatorcontrib>Relling, M V</creatorcontrib><creatorcontrib>Tantisira, K G</creatorcontrib><title>A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment</title><title>The pharmacogenomics journal</title><addtitle>Pharmacogenomics J</addtitle><addtitle>Pharmacogenomics J</addtitle><description>Treatment with glucocorticoids is associated with lower bone mineral density (BMD). We performed a genome-wide association study to analyze interactive effects between genotypes and cumulative dose of prednisone (PD) over 4.3 years of follow-up period on the final BMD
Z
-scores in 461 white children from the Childhood Asthma Management Program. No variants met the conventional criteria for genome-wide significance, and thus we looked for evidence of replication. The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen. Among them, rs6461639 (interaction
P
=1.88 × 10
−5
in the CAMP population) showed a significant association with the final BMD
Z
-scores in the ALL population (
P
=0.016). The association of the ALL population was only present after correction for the anti-metabolite treatment arm (high vs low dose). We have identified a novel SNP, rs6461639, showing a significant effect on the final BMD
Z
-scores in two independent pediatric populations after long-term high-dose PD treatment.</description><subject>45/43</subject><subject>631/208/2489</subject><subject>692/499</subject><subject>Absorptiometry, Photon</subject><subject>Acute lymphoblastic leukemia</subject><subject>Age Factors</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Anti-Asthmatic Agents - adverse effects</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Asthma</subject><subject>Asthma - drug therapy</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone density</subject><subject>Bone Density - drug effects</subject><subject>Bone Density - genetics</subject><subject>Bone mineral density</subject><subject>Child</subject><subject>Children</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Genome-wide association studies</subject><subject>Genome-Wide Association Study</subject><subject>Genomes</subject><subject>Genotype</subject><subject>Glucocorticoids</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - adverse effects</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Lymphatic leukemia</subject><subject>Male</subject><subject>Oncology</subject><subject>original-article</subject><subject>Pediatrics</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenomic Variants</subject><subject>Pharmacotherapy</subject><subject>Phenotype</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</subject><subject>Prednisone</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - adverse effects</subject><subject>Psychopharmacology</subject><subject>Replication</subject><subject>Risk Factors</subject><subject>Single-nucleotide polymorphism</subject><subject>Time Factors</subject><subject>Tomography, Spiral Computed</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>1470-269X</issn><issn>1473-1150</issn><issn>1473-1150</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNks9rFDEUxwex2Fo9eZeAF8HOmmTyay5CKVoLBS8K3kIm82Y2y0yyJhmX_vdm3VqqSOkpL7xPvt-8x7eqXhG8IrhR7_N2s6KY8FVLn1QnhMmmJoTjp79rXFPRfj-unqe0wZgIItWz6pgKxQVl8qTanaMRPGRn0WBsDhGZlIJ1JkOPdi6v0RR2aHDeTKgLHtDsPMRy6cEnl2-Q88iu3dRH8MgMGYpAeeLHupQzGqfFBhti0Q-uTyhHMHkGn19UR4OZEry8PU-rb58-fr34XF9_uby6OL-uLccy143EjFolMOedogOXqpNYYiMEAYGpwtB0YmBdZ4jkLWDc855R0lCqCPSma06rDwfd7dLN0NtiXX6vt9HNJt7oYJz-u-PdWo_hp2atKvq0CLy9FYjhxwIp69klC9NkPIQlaaJaohRmrHkESoXghEpW0Df_oJuwxLLkpKkgnDe4YeQhqniWOSVr20K9O1A2hpQiDHfTEaz3CdElIXqfEN3u53l9fyF37J9IFODsAKTS8iPEe6b_0fsFTvjFug</recordid><startdate>20170301</startdate><enddate>20170301</enddate><creator>Park, H-W</creator><creator>Tse, S</creator><creator>Yang, W</creator><creator>Kelly, H W</creator><creator>Kaste, S C</creator><creator>Pui, C-H</creator><creator>Relling, M V</creator><creator>Tantisira, K G</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170301</creationdate><title>A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment</title><author>Park, H-W ; Tse, S ; Yang, W ; Kelly, H W ; Kaste, S C ; Pui, C-H ; Relling, M V ; Tantisira, K G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>45/43</topic><topic>631/208/2489</topic><topic>692/499</topic><topic>Absorptiometry, Photon</topic><topic>Acute lymphoblastic leukemia</topic><topic>Age Factors</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Anti-Asthmatic Agents - adverse effects</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Asthma</topic><topic>Asthma - drug therapy</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone density</topic><topic>Bone Density - drug effects</topic><topic>Bone Density - genetics</topic><topic>Bone mineral density</topic><topic>Child</topic><topic>Children</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Genome-wide association studies</topic><topic>Genome-Wide Association Study</topic><topic>Genomes</topic><topic>Genotype</topic><topic>Glucocorticoids</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - adverse effects</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Lymphatic leukemia</topic><topic>Male</topic><topic>Oncology</topic><topic>original-article</topic><topic>Pediatrics</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenomic Variants</topic><topic>Pharmacotherapy</topic><topic>Phenotype</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy</topic><topic>Prednisone</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - adverse effects</topic><topic>Psychopharmacology</topic><topic>Replication</topic><topic>Risk Factors</topic><topic>Single-nucleotide polymorphism</topic><topic>Time Factors</topic><topic>Tomography, Spiral Computed</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, H-W</creatorcontrib><creatorcontrib>Tse, S</creatorcontrib><creatorcontrib>Yang, W</creatorcontrib><creatorcontrib>Kelly, H W</creatorcontrib><creatorcontrib>Kaste, S C</creatorcontrib><creatorcontrib>Pui, C-H</creatorcontrib><creatorcontrib>Relling, M V</creatorcontrib><creatorcontrib>Tantisira, K G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The pharmacogenomics journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, H-W</au><au>Tse, S</au><au>Yang, W</au><au>Kelly, H W</au><au>Kaste, S C</au><au>Pui, C-H</au><au>Relling, M V</au><au>Tantisira, K G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment</atitle><jtitle>The pharmacogenomics journal</jtitle><stitle>Pharmacogenomics J</stitle><addtitle>Pharmacogenomics J</addtitle><date>2017-03-01</date><risdate>2017</risdate><volume>17</volume><issue>2</issue><spage>180</spage><epage>185</epage><pages>180-185</pages><issn>1470-269X</issn><issn>1473-1150</issn><eissn>1473-1150</eissn><abstract>Treatment with glucocorticoids is associated with lower bone mineral density (BMD). We performed a genome-wide association study to analyze interactive effects between genotypes and cumulative dose of prednisone (PD) over 4.3 years of follow-up period on the final BMD
Z
-scores in 461 white children from the Childhood Asthma Management Program. No variants met the conventional criteria for genome-wide significance, and thus we looked for evidence of replication. The top 100-ranked single-nucleotide polymorphisms (SNPs) were then carried forward replication in 59 children with acute lymphoblastic leukemia (ALL) exposed to large fixed doses of PD as part of their chemotherapeutic regimen. Among them, rs6461639 (interaction
P
=1.88 × 10
−5
in the CAMP population) showed a significant association with the final BMD
Z
-scores in the ALL population (
P
=0.016). The association of the ALL population was only present after correction for the anti-metabolite treatment arm (high vs low dose). We have identified a novel SNP, rs6461639, showing a significant effect on the final BMD
Z
-scores in two independent pediatric populations after long-term high-dose PD treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26856247</pmid><doi>10.1038/tpj.2015.92</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-269X |
| ispartof | The pharmacogenomics journal, 2017-03, Vol.17 (2), p.180-185 |
| issn | 1470-269X 1473-1150 1473-1150 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4980282 |
| source | Springer Nature |
| subjects | 45/43 631/208/2489 692/499 Absorptiometry, Photon Acute lymphoblastic leukemia Age Factors Anti-Asthmatic Agents - administration & dosage Anti-Asthmatic Agents - adverse effects Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Asthma Asthma - drug therapy Biomedical and Life Sciences Biomedicine Bone density Bone Density - drug effects Bone Density - genetics Bone mineral density Child Children Drug Administration Schedule Female Gene Expression Genome-wide association studies Genome-Wide Association Study Genomes Genotype Glucocorticoids Glucocorticoids - administration & dosage Glucocorticoids - adverse effects Human Genetics Humans Lymphatic leukemia Male Oncology original-article Pediatrics Pharmacogenetics Pharmacogenomic Variants Pharmacotherapy Phenotype Polymorphism, Single Nucleotide Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Prednisone Prednisone - administration & dosage Prednisone - adverse effects Psychopharmacology Replication Risk Factors Single-nucleotide polymorphism Time Factors Tomography, Spiral Computed Treatment Outcome United States |
| title | A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A26%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20genetic%20factor%20associated%20with%20low%20final%20bone%20mineral%20density%20in%20children%20after%20a%20long-term%20glucocorticoids%20treatment&rft.jtitle=The%20pharmacogenomics%20journal&rft.au=Park,%20H-W&rft.date=2017-03-01&rft.volume=17&rft.issue=2&rft.spage=180&rft.epage=185&rft.pages=180-185&rft.issn=1470-269X&rft.eissn=1473-1150&rft_id=info:doi/10.1038/tpj.2015.92&rft_dat=%3Cproquest_pubme%3E2615530341%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c507t-37042c86055b82f578b7070a661e60280e3b6f4bba1759e00d5d42132281edab3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1884217499&rft_id=info:pmid/26856247&rfr_iscdi=true |